Analysts anticipate Roivant Sciences to report an earnings per share (EPS) of $-0.16. The announcement from Roivant Sciences is eagerly anticipated, with investors seeking news of surpassing estimates ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Roivant Sciences Ltd. (NASDAQ:ROIV) while keeping the price target the same at $18. The reiteration comes after the company appointed ...

Entrepreneur and politician Vivek Ramaswamy made much of his fortune founding biotechnology companies and trading their stocks, but now the former GOP presidential candidate and current contender for ...

Real-time index price for U.S. Semiconductors Index (DSSC), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Cancer organizations are urging researchers, oncologists, and other stakeholders to advocate for cancer research.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Strive, co-founded by Vivek Ramaswamy, has announced a raise of $750 million which will go to Bitcoin purchases and the ...

Major US indexes finished in the green on Wednesday, May 7, after a volatile session […] Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C ...

Vivek Ramaswamy, who is CEO of Roivant Sciences and still chair of Axovant’s board of directors, said: “I would like to thank David for his commitment to Axovant over the past 10 months ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.